TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8667183
Drug: Fentanyl (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl (0.25 mg/70 kg i.v.)
Study: 8667183
Drug: Alfentanil (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfentanil (1 mg/70 kg i.v.)
Study: 8667183
Drug: Alfentanil (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfentanil (2 mg/70 kg i.v.)
Study: 8667183
Drug: Naloxone (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone (10 mg/70 kg i.m.)
Study: 30726224
Drug: Single-dose sulfadoxine-pyrimethamine
Normalized name: pyrimethamine / sulfadoxine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose sulfadoxine-pyrimethamine (SP) and 3 doses of amodiaquine (AQ) every three months
Study: 29024410
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg once daily (OD) for 8 weeks
Study: 29024410
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg OD for 8 weeks
Study: 26743775
Drug: 100 µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 µg glucagon
Study: 26743775
Drug: 200 µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 µg glucagon
Study: 26743775
Drug: 300 µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 µg glucagon
Study: 22974886
Drug: Liposomal amphotericin
Normalized name: Liposomal amphotericin B
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Liposomal amphotericin B (3 mg/kg/d; group A)
Study: 22974886
Drug: Fluconazole (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluconazole (800 mg loading dose and thereafter 400 mg/d; group B)
Study: 20102150
Drug: RWJ-671818 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: RWJ-671818 at 30 mg/kg
Study: 20102150
Drug: RWJ-671818 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: RWJ-671818 at 50 mg/kg
Study: 20102150
Drug: RWJ-671818 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: RWJ-671818 at 0.1 mg/kg, i.v.
Study: 20102150
Drug: RWJ-671818 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: RWJ-671818 at 1.0 mg/kg, i.v.
Study: 16935912
Drug: Abatacept 2
Normalized name: abatacept 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abatacept 2 mg/kg during double-blind phase
Study: 16935912
Drug: Abatacept 10
Normalized name: Abatacept
DrugBank: Abatacept (DB01281)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Abatacept 10 mg/kg during LTE
Study: 8714425
Drug: Yohimbine 15
Normalized name: YOHIMBINE
DrugBank: Yohimbine (DB01392)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yohimbine 15 mg daily for 7 weeks
Study: 8714425
Drug: Yohimbine 15
Normalized name: YOHIMBINE
DrugBank: Yohimbine (DB01392)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yohimbine 15 mg daily
Study: 6336944
Drug: Retinoid therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Retinoid therapy
Study: 31517964
Drug: Prize-linked savings
Normalized name: riboflavin 5'-phosphate
DrugBank: Flavin mononucleotide (DB03247)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prize-linked savings accounts with 1000 Kenya shillings (US 10) and weekly lottery-based rewards contingent on growth in savings balance
Study: 24680227
Drug: Cognitive therapy
Normalized name: cognitive therapy software
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive therapy (CT), 16-20 sessions over 12-14 weeks
Study: 17888019
Drug: Immediate implant
Normalized name: IR-3535
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate implant placement in extraction sockets exhibiting periapical pathology (test group)
Study: 17888019
Drug: Immediate implant
Normalized name: IR-3535
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate implant placement in extraction sockets without periapical pathology (control group)
Study: 15130377
Drug: Clomiphene citrate
Normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clomiphene citrate (CC) alone, Group A
Study: 15130377
Drug: Clomiphene citrate
Normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clomiphene citrate (CC) and rosiglitazone in combination, Group C
Study: 7962674
Drug: Ketorolac 15
Normalized name: ketorolac 15.75 mg/inh nasal spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketorolac 15 mg
Study: 29300259
Drug: Pharmacologic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacologic therapy for urgency-predominant urinary incontinence
Study: 29300259
Drug: Sleeping medications
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sleeping medications (used by 13% of participants 3 or more times per week)
Study: 27017403
Drug: Interferential current
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferential current stimulation (IFCS) applied to submandibular and sublingual glands.
Study: 23685640
Drug: Sodium bicarbonate
Normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium bicarbonate infusion (n = 215), 0.5 mEq/kg/hr for the first hour and then 0.2 mmol/kg/hr for 23 hours
Study: 23685640
Drug: Sodium chloride
Normalized name: Sodium Chloride
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium chloride infusion (n = 212)
Study: 16365063
Drug: 3 g
Normalized name: Molds 3 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 g ALA/d from flaxseed oil capsules
Study: 16365063
Drug: Olive oil
Normalized name: Olive Oil
DrugBank: Olive oil (DB09567)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olive oil placebo capsules
Study: 11038148
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose Iloprost (50-100 microgram twice a day)
Study: 11038148
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose Iloprost (150-200 microgram twice a day)
Study: 1358139
Drug: Classical antihistamines
Normalized name: Ahist Antihistamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Classical antihistamines
Study: 23643848
Drug: Pumice treatment
Normalized name: Pumice
DrugBank: Pumice (DB14374)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pumice treatment
Study: 16638294
Drug: Sequential MV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential MV group (n = 47)
Study: 1673977
Drug: Terfenadine 180
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terfenadine 180 mg orally
Study: 1673977
Drug: Ipratropium bromide
Normalized name: Ipratropium Bromide
DrugBank: Ipratropium (DB00332)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ipratropium bromide (IB) 0.5 mg nebulized aerosol
Study: 1673977
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Terfenadine and Ipratropium bromide
Study: 6460207
Drug: Zimelidine (100,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zimelidine (100, 200 or 300 mg, p.o.)
Study: 6460207
Drug: Zimelidine and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zimelidine and alcohol combination
Study: 26883950
Drug: 40 International
Normalized name: CONDOM,INTERNAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 International Units oxytocin once daily
Study: 25764160
Drug: Immunotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunotherapy with pegylated IFN‐α (subcutaneously weekly)
Study: 23846820
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of low‐dose spironolactone (50 mg/d) and metformin (1000 mg/d)
Study: 23846820
Drug: Low‐dose spironolactone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low‐dose spironolactone (50 mg/d)
Study: 20618506
Drug: Intravenous siplizumab
Normalized name: teplizumab
DrugBank: Teplizumab (DB06606)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous siplizumab (0.012 mg/kg and 0.04 mg/kg every 2 weeks for 8 doses)
Study: 20618506
Drug: Subcutaneous siplizumab
Normalized name: teplizumab
DrugBank: Teplizumab (DB06606)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous siplizumab (5 mg x 12 weeks, 5 mg x 6 weeks + placebo x 6 weeks, 7 mg x 4 weeks + placebo x 8 weeks)
Study: 12744899
Drug: Heptavalent pneumococcal
Normalized name: botulinum neurotoxin B immune FAB2
DrugBank: Equine Botulinum Neurotoxin B Immune FAB2 (DB13903)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heptavalent pneumococcal conjugate vaccine (PCV) conjugated to outer membrane protein of Neisseria meningitidis serogroup b, administered at 2, 4, 6, and 12 months of age.
Study: 12744899
Drug: Heptavalent pneumococcal
Normalized name: botulinum neurotoxin B immune FAB2
DrugBank: Equine Botulinum Neurotoxin B Immune FAB2 (DB13903)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heptavalent pneumococcal conjugate vaccine (PCV) after the 12 month dose.
Study: 10567989
Drug: Sterilized solution
Normalized name: Steril-Eyes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sterilized solution (Rhinomer, Zyma SA, Nyon, France)
Study: 9117049
Drug: Active antibiotic
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active antibiotic pastille
Study: 22736123
Drug: Traditional fluid
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional fluid therapy
Study: 28628684
Drug: Two treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two treatment sessions using BodyFX bipolar RF device
Study: 28628684
Drug: Three treatment
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three treatment sessions using BodyFX bipolar RF device
Study: 28628684
Drug: Eight weekly
Normalized name: OC Eight
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eight weekly sessions using BodyFX bipolar RF device
Study: 9439085
Drug: Naratriptan 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naratriptan 0.1 mg
Study: 9439085
Drug: All doses
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All doses of Naratriptan
Study: 8502260
Drug: Synthetic human
Normalized name: Synthetic human secretin
DrugBank: Secretin human (DB09532)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Synthetic human growth hormone (Protropin)
Study: 27388361
Drug: 0.5% chlorhexidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% chlorhexidine gluconate (CHG) in aqueous solution
Study: 23873319
Drug: Group 1:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 1: 550 μg fluoride (F)/g, pH 4.5
Study: 23873319
Drug: Group 2:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 2: 1,100 μg F/g, pH 7.0
Study: 23873319
Drug: Group 3:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 3: 550 μg F/g, pH 7.0
Study: 20103775
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D supplementation (100,000 U of oral vitamin D2 at baseline and 10 weeks)
Study: 18996875
Drug: Dual-fortified salt
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual-fortified salt with iron as micronized ground ferric pyrophosphate (MGFePP) at 2 mg/g salt
Study: 18996875
Drug: Dual-fortified salt
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual-fortified salt with iron as encapsulated ferrous fumarate (EFF) at 2 mg/g salt
Study: 9195022
Drug: Home-based physical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home-based physical therapy (number of visits determined by patient response)
Study: 3011440
Drug: Perindopril (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perindopril (8 mg orally)
Study: 29742942
Drug: Combined low
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined low dose vaginal misoprostol plus Foley catheter
Study: 29240860
Drug: ixekizumab 80
Normalized name: ixekizumab 80 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: ixekizumab 80 mg injection every 2 weeks after a 160 mg starting dose
Study: 18763027
Drug: etanercept 50
Normalized name: etanercept 50 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: etanercept 50 mg twice weekly
Study: 26348584
Drug: Low-dose aripiprazole
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose aripiprazole added to antidepressant therapy
Study: 26348584
Drug: Pooled response
Normalized name: Besponsa
DrugBank: Inotuzumab ozogamicin (DB05889)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pooled response rates across phases and treatments
Study: 23557594
Drug: Rotigotine transdermal
Normalized name: Rotigotine Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rotigotine transdermal system (2-16 mg/24 h)
Study: 18786961
Drug: Intramuscular injection
Normalized name: rabies, intramuscular injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular injection of 30 microg adrenaline
Study: 18786961
Drug: Saline injection
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline injection (0.30 ml)
Study: 11159240
Drug: 75 mg
Normalized name: talc 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg hyperbaric lidocaine 5% (n = 100)
Study: 11159240
Drug: 12 mg
Normalized name: pectin 12 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 mg hyperbaric bupivacaine 0.75% (n = 100)
Study: 9628552
Drug: Caffeine intake
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Caffeine intake 300 to 700 mg/d
Study: 9628552
Drug: Caffeine intake
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Caffeine intake >700 mg/d
Study: 9628552
Drug: Caffeine intake
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Caffeine intake >300 mg/d from coffee (smoking women)
Study: 9628552
Drug: Nonsmoking women
Normalized name: Arthricare for Women Moisturizing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonsmoking women with caffeine intake <300 mg/d
Study: 3060967
Drug: Cefotetan 2
Normalized name: cefotetan 2000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefotetan 2 g administered during induction of anesthesia
Study: 31306889
Drug: Individualized disease-
Normalized name: LYME DISEASE VACCINE
DrugBank: Lyme disease vaccine (recombinant OspA) (DB00045)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individualized disease- and treatment-related information
Study: 19367181
Drug: Minimal enteral
Normalized name: Centipeda minima whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minimal enteral feeding (MEF) initiated 5 days after bowel reintegration, increased by 12 mL/kg/day
Study: 14728005
Drug: Clopidogrel plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel plus aspirin (loading dose of 300 mg followed by 75 mg daily)
Study: 9517604
Drug: Intensive smoking
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive smoking cessation program with inhaled bronchodilator
Study: 8000984
Drug: Low-dose mitoxantrone
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose mitoxantrone (MX)
Study: 3149291
Drug: atenolol, 50-100
Approvals — FDA: no, EMA: no, PMDA: no
Description: atenolol, 50-100 mg
Study: 3149291
Drug: trichloromethiazide, 2-4
Approvals — FDA: no, EMA: no, PMDA: no
Description: trichloromethiazide, 2-4 mg
Study: 3149291
Drug: slow release
Normalized name: Slow Release Iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: slow release nifedipine, 40-80 mg
Study: 3149291
Drug: captopril, 37.5-75
Approvals — FDA: no, EMA: no, PMDA: no
Description: captopril, 37.5-75 mg
Study: 31583699
Drug: Melatonin 8
Normalized name: Calcium Carbonate/Melatonin 84 MG-5 MG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin 8 mg
Study: 31583699
Drug: Comparison of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of placebo to any dose of melatonin
Study: 26921116
Drug: Individualized metacognitive
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individualized metacognitive therapy program (MCT+)
Study: 21962194
Drug: Solvent controls
Normalized name: solvent yellow 18
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solvent controls (plain distilled water and water-ethanol (95%) solution)
Study: 18923232
Drug: Nicotine vaccine
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotine vaccine
Study: 18923232
Drug: Antiangiotensin vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiangiotensin vaccine
Study: 18923232
Drug: Anti-obesity vaccine
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-obesity vaccine
Study: 18923232
Drug: Vaccine targeting
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccine targeting heat shock proteins and oxidized low-density lipoprotein
Study: 18923232
Drug: Vaccine to
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccine to inhibit cholesteryl ester transfer protein
Study: 17041286
Drug: Adherence to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adherence to antipsychotic medication
Study: 17041286
Drug: Mediating variables
Normalized name: Ferric carbonate, ferric hydroxide, ferrous hydroxide (variable mixture)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mediating variables (symptomatic impairment, global functioning, medication side effects)
Study: 9542560
Drug: Deltoid injection
Normalized name: Ambrosia deltoidea pollen
DrugBank: Ambrosia deltoidea pollen (DB10765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deltoid injection of scopolamine 6 micrograms/kg plus morphine 200 micrograms/kg
Study: 9542560
Drug: Gluteal injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gluteal injection of scopolamine 6 micrograms/kg plus morphine 200 micrograms/kg
Study: 8168033
Drug: Double beta‐lactam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double beta‐lactam combination (Group C)
Study: 8168033
Drug: Antibiotic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic therapy without additional antifungal therapy
Study: 2462402
Drug: Alfuzosin (7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfuzosin (7.5 mg or 10 mg/day)
Study: 22965961
Drug: mFOLFOX6/cediranib 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: mFOLFOX6/cediranib 20 mg
Study: 17325505
Drug: Remifentanil (0-15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil (0-15 ng/ml) and inhaled sevoflurane (0-6 vol%)
Study: 11472709
Drug: L-methionine (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-methionine (100 mg/kg at -6 hours)
Study: 9787721
Drug: Medication +
Normalized name: Medicated Shampoo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication + diet
Study: 7664725
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose of aqueous retinyl palmitate oral solution
Study: 773392
Drug: Quinidine polygalacturonate
Normalized name: QUINIDINE POLYGALACTURONATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinidine polygalacturonate (short-acting), 4 daily doses
Study: 773392
Drug: Quinidine arabogalactan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinidine arabogalactan sulphate (long-acting), 2 daily doses
Study: 14700452
Drug: Paroxetine controlled-release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paroxetine controlled-release (CR)
Study: 21895859
Drug: Paroxetine immediate-release
Normalized name: paroxetine Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paroxetine immediate-release (IR)
Study: 17895776
Drug: Right-arm injection
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Right-arm injection of contrast material (80 mL, iodine concentration 300 mg/mL, 2 mL/s injection rate)
Study: 17895776
Drug: Left-arm injection
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Left-arm injection of contrast material (80 mL, iodine concentration 300 mg/mL, 2 mL/s injection rate)
Study: 11525314
Drug: Ro70-0004 (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ro70-0004 (5 mg)
Study: 9350563
Drug: Triclosan-containing gel/dentifrice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triclosan-containing gel/dentifrice combination
Study: 9350563
Drug: Control gel/dentifrice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control gel/dentifrice combination
Study: 1778859
Drug: Cefpirome 1
Normalized name: cefpirome 100 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefpirome 1 or 2 g bd for 5-9 days
Study: 29288184
Drug: Non-surgical treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-surgical treatment (pressure bandages, (bed) rest and wound care)
Study: 29288184
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment (debridement, antibiotics and implant retention (DAIR))
Study: 29288184
Drug: Non-surgical treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-surgical treatment followed by DAIR if persistent leakage at day 16-17
Study: 24792311
Drug: Bupivacaine block
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine block (0.25%) injected into trocar incision sites, 10 mL for incisions 8 mm or greater, 5 mL for incisions 5 mm or less.
Study: 16166442
Drug: Celecoxib (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celecoxib (400 mg p.o. twice daily) plus docetaxel (75 mg/m(2) every 3 weeks)
Study: 8940729
Drug: Hematopoietic growth
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hematopoietic growth factors (HGF) such as G-CSF and GM-CSF
Study: 1565246
Drug: EMG-assisted botulinum
Normalized name: Clostridium botulinum
DrugBank: Clostridium botulinum (DB14223)
Approvals — FDA: no, EMA: no, PMDA: no
Description: EMG-assisted botulinum toxin (BOTOX) injections, N = 28
Study: 1565246
Drug: Botulinum toxin
Normalized name: Botulinum toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum toxin (BOTOX) injections without EMG assistance, N = 24
Study: 3907967
Drug: Norethisterone oenanthate
Normalized name: Oenanthic acid
DrugBank: Norethindrone enanthate (DB14678)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norethisterone oenanthate (NET OEN) 50 mg alone
Study: 3907967
Drug: Norethisterone oenanthate
Normalized name: Oenanthic acid
DrugBank: Norethindrone enanthate (DB14678)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norethisterone oenanthate (NET OEN) 50 mg with estradiol valerate (E2 Val.) 5 mg